Medical News

RSS

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

TransTech Pharma, Inc and Forest Laboratories, Inc., today announced that TransTech Pharma and Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. have entered into a license agreement for the development and commercialization of small molecule compounds discovered and developed by TransTech Pharma.

9 Jun 2010

Researchers look at exercise as new way to slow degenerative processes of ALS

University of Alberta researchers are looking at exercise as a new way to slow the degenerative processes of ALS, commonly known as Lou Gehrig's disease. Dr. Kelvin Jones, a recipient of this year's ALS Canada Discovery Grant, has been pioneering research in this field for four years, using mice genetically altered to present familial ALS. He's found that exercise has a positive impact on the mice, slowing the disease significantly.

9 Jun 2010

UNITAID concerned about infant HIV medication shortage, drug company says supply is sufficient

Bristol-Myers Squibb's plans this month to close its plant in Meymac, France, that manufactures "the last therapeutic option" for HIV-positive babies has drawn criticism from UNITAID, Reuters reports. In an open letter published in the Lancet, UNITAID writes that "[c]losing this factory means that 4,000 to 7,000 babies currently enrolled in treatment plans in developing countries through UNITAID could be left without the medicines they need."

9 Jun 2010

In the news: Senate and jobs bill; Obama appeals to seniors; States' Medicaid squeeze; Beyond COBRA

Today's headlines highlights President Obama's planned visit to a senior center to tout health reform, while several columns examine insurance issues, what doctors say about electronic medical record goals and military treatment of traumatic brain injuries is investigated.

9 Jun 2010

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Impax Laboratories, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

DSM announces agreements with Biomedical Structures, Cortland and Secant Medical

DSM, which created and manufactures Dyneema Purity, the world's strongest Medical grade fiber, today announced agreements with Biomedical Structures, Cortland Company and Secant Medical. These companies' experience in processing Dyneema Purity fiber in biomedical textile structures offers medical device companies the ability to use various constructions of Dyneema Purity, including the recently launched Dyneema Purity BLUE, in commercial medical devices.

9 Jun 2010

Cellectis bioresearch, Lonza collaborate in development, commercialization of bioengineered cell line

Cellectis bioresearch, the French genome customization specialist and a commercial subsidiary of Cellectis, and Lonza, a world leader in biotechnology production, announce today that the companies have entered into an agreement for the development and commercialization of a bioengineered cell line.

9 Jun 2010

CPRIT presents a $300,000 check to UNT Health Science Center for cancer research

The Cancer Prevention and Research Institute of Texas recently presented a $300,000 check to the University of North Texas Health Science Center. The check was accepted by the UNT Health Science Center Provost Thomas Yorio, Ph.D., and Richard Kurz, Ph.D., dean of the School of Public Health.

9 Jun 2010

Biogen, Elan launch My MS Health, a web-based PRO research program

Biogen Idec and Elan Corporation, plc, in collaboration with EPI-Q, Inc. and Avatar International, LLC, today announced the launch of My MS Health, a first-of-its-kind, web-based, patient-reported outcomes research program. My MS Health is designed to track and provide instant reports on patient function and quality of life using validated measures over time.

9 Jun 2010

Gates Foundation announces 5-year, $1.5 billion commitment for maternal, child health

During the Women Deliver conference on Monday Melinda Gates announced that the Bill & Melinda Gates Foundation "will spend $1.5 billion over the next five years on maternal and child health, family planning and nutrition in developing countries, a pledge that signals a new focus for the foundation known for concentrating on vaccines and AIDS," the Wall Street Journal reports (Jordan, 6/7).

9 Jun 2010

American Diversified Holdings enters Mobile Health Care Market

American Diversified Holdings Corporation has today announced its intention to enter the Mobile Health Care Market as the medical profession gears up to go electronic not only for medical records but also for direct patient monitoring and information.

9 Jun 2010

Inquiry into the hospital acquired killer bug starts

A Second World War veteran John Boyle died of Clostridium difficile infection after being admitted to hospital for the first time at the age of 90. He was diagnosed with the infection on January 25 this year and succumbed to it two weeks later. He was one of 18 patients to die at a Scottish hospital when the outbreak of this hospital-acquired infection was reported.

8 Jun 2010

Waste incinerator spewing chemical waste: Says worried Brisbane Lord Mayor

A council commissioned study into the Ace Waste incinerator at Willawong showed that the residents and businesses around the facility were at potential risk of exposure to chemical emissions. The incinerator at Willawong is used to dispose of medical and chemical pollutants that can cause cancer when people are exposed to high concentrations. Brisbane Lord Mayor Campbell Newman revealed this last night. Premier Anna Bligh however denies that there is such a risk. She has assured that the incinerator is safe and there have been no problems for the past twenty year.

8 Jun 2010

Finished school – better health for Indigenous Australians

A new report prepared by the Australian Bureau of Statistics (ABS) has found that indigenous Australians who go on to complete their school education fare much better health wise than those who do not.

8 Jun 2010

USTPO awards Melior Discovery Notice of Allowance for type II diabetes and obesity drug candidate

Melior Discovery, Inc. announced today the United States Patent and Trademark Office (USTPO) has awarded a Notice of Allowance for a broad patent application covering the Company's use of MLR-1023 for, among other things, the treatment of type II diabetes and obesity. The patent will cover use of MLR-1023 for the treatment of type II diabetes, obesity and metabolic syndrome, including its use in combination with other compounds and as a component in other drugs.

8 Jun 2010

Argos presents positive AGS-003 Phase 2 data for newly diagnosed advanced renal cell carcinoma at ASCO

Argos Therapeutics today announced the presentation of positive interim data from a Phase 2 trial that evaluated the clinical activity, safety and immune response of AGS-003 treatment, given in combination with sunitinib, in patients with newly diagnosed advanced renal cell carcinoma (RCC). The data were discussed June 7 in a poster session at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

8 Jun 2010

America's Minority Health Network signs LOI to acquire Spectrum Health Network

AMHN, Inc., announced today that it entered into a Letter of Intent ("LOI") with Gordon Communications, Inc., a Delaware corporation, to acquire Spectrum Health Network, Inc. ("Spectrum"). Spectrum is a digital signage waiting room network built for the multi-specialty group practice and independent physician associations.

8 Jun 2010

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

NanoViricides, Inc. reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.

8 Jun 2010

Immunomedics reports encouraging results from TF2 Phase I studies for colorectal cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that TF2, a proprietary bispecific antibody, has shown selective tumor localization and minimal normal tissue retention in two early Phase I studies in patients with colorectal cancer.

8 Jun 2010

HPV-positive tumor status is strong prognostic factor for head, neck cancer

Oropharyngeal cancer patients whose tumors in the upper part of the throat test positively for the human papillomavirus (HPV) have better overall survival than patients with HPV-negative disease, researchers from The University of Texas MD Anderson Cancer Center report in a study published in The New England Journal of Medicine.

8 Jun 2010

Medical News

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

Researchers look at exercise as new way to slow degenerative processes of ALS

UNITAID concerned about infant HIV medication shortage, drug company says supply is sufficient

In the news: Senate and jobs bill; Obama appeals to seniors; States' Medicaid squeeze; Beyond COBRA

Endo, Penwest announce settlement of OPANA ER litigation with Impax

DSM announces agreements with Biomedical Structures, Cortland and Secant Medical

Cellectis bioresearch, Lonza collaborate in development, commercialization of bioengineered cell line

CPRIT presents a $300,000 check to UNT Health Science Center for cancer research

Biogen, Elan launch My MS Health, a web-based PRO research program

Gates Foundation announces 5-year, $1.5 billion commitment for maternal, child health

American Diversified Holdings enters Mobile Health Care Market

Inquiry into the hospital acquired killer bug starts

Waste incinerator spewing chemical waste: Says worried Brisbane Lord Mayor

Finished school – better health for Indigenous Australians

USTPO awards Melior Discovery Notice of Allowance for type II diabetes and obesity drug candidate

Argos presents positive AGS-003 Phase 2 data for newly diagnosed advanced renal cell carcinoma at ASCO

America's Minority Health Network signs LOI to acquire Spectrum Health Network

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

Immunomedics reports encouraging results from TF2 Phase I studies for colorectal cancer

HPV-positive tumor status is strong prognostic factor for head, neck cancer

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News